TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04263220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Industrial passive exoskeleton with a specific value of the torque of the spring for supporting the back
Description: Both exoskeleton types are passive exoskeletons for supporting the back. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Industrial passive exoskeleton with a specific value of the torque of the spring for supporting the back
Description: Both exoskeleton types are passive exoskeletons for supporting the back. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protocol will be performed without exoskeleton
Description: protocol will be performed without exoskeleton
Study: NCT01006174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soybean Oil
Description: Depending on the experimental group assigned, each subject which will be given one of three different amounts of soybean oil that is added to a salad.
Study: NCT03958136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcome (PRO)
Description: Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcome (PRO)
Description: Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.
Study: NCT01006174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soybean Oil
Description: Depending on the experimental group assigned, each subject which will be given one of three different amounts of soybean oil that is added to a salad.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soybean Oil
Description: Depending on the experimental group assigned, each subject which will be given one of three different amounts of soybean oil that is added to a salad.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canola Oil
Description: Depending on the experimental group assigned, each subject which will be given one of three different amounts of canola oil that is added to a salad.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canola Oil
Description: Depending on the experimental group assigned, each subject which will be given one of three different amounts of canola oil that is added to a salad.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canola Oil
Description: Depending on the experimental group assigned, each subject which will be given one of three different amounts of canola oil that is added to a salad.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter
Description: Depending on the experimental group assigned, each subject which will be given one of three different amounts of butter that is added to a salad.
Study: NCT01478737

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vitrectomy
Description: Vitrectomy only
Study: NCT01224028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: oral
Study: NCT01006174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter
Description: Depending on the experimental group assigned, each subject which will be given one of three different amounts of butter that is added to a salad.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter
Description: Depending on the experimental group assigned, each subject which will be given one of three different amounts of butter that is added to a salad.
Study: NCT03477097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition, exercise and social network intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition, exercise and social network intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition, exercise and social network intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition, exercise and social network intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition, exercise and social network intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition, exercise and social network intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition, exercise and social network intervention
Study: NCT00905723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol
Description: 1 mg daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoflavone
Description: 150 mg isoflavone daily for 6 months
Study: NCT03477097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition, exercise and social network intervention
Study: NCT02719600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Evaluation of observational motor learning using virtual reality

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: Evaluation of observational motor learning using virtual reality
Study: NCT00905723

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill daily for six months
Study: NCT02925663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFI-E
Description: This is 10 web-based modules addressing foundational EF skills. Each online module will be accompanied by a videoconference with a therapist to review the skills and problem solve around adolescent-identified goals.
Study: NCT03016026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS
Description: Undergo an ERAS program
Study: NCT01170117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Dosing of olanzapine will begin at 2.5 mg and will be titrated to a maximum dose of 10 mg. The target dose of 10 mg of olanzapine was selected because published data from studies that used this dose indicated that it was helpful to patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control Group will receive placebo pill
Study: NCT03720821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training + fMRI
Description: Consented subjects will be asked to participate in the study for up to five months. Patients will be consented at the Washington University Department of Anesthesiology and will be asked to complete baseline resilience, pain, and anxiety and depression questionnaires, along with cognitive tests by pencil and paper that will be administered by a member of the research team. The participants will also be required to complete a computer-based Trails-making test, Color Match test, and NCPT (Neurocognitive Performance Test) battery at baseline, and undergo a functional magnetic resonance imaging (fMRI) session.~All subjects will be asked to complete the three paper-pencil and computer-based measurements along with repeat pain questionnaire again 1-3 days after completion of training, undergo a second fMRI scan at that time, and complete the questionnaires again 3 months after the completion of training.
Study: NCT02858154

Intervention type: OTHER
Group type: OTHER
Intervention: HFNC
Description: All subjects will have a 3-4 hour intervention of HFNC to test effectiveness and safety for treating OSA

Intervention type: OTHER
Group type: OTHER
Intervention: Low flow oxygen by nasal cannula
Description: All subjects will have a 6 to 8 hours intervention during the clinically scheduled PSG of titration of oxygen by nasal cannula (standard of care) to manage sleep apnea
Study: NCT04627493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise
Description: Participants will participate in an online exercise program on Zoom delivered by Registered Kinesiologists and Physiotherapists three times a week.
Study: NCT04133298

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunneling with laser de-epithelized gingival graft
Description: After the administration of local anesthesia, the dimension of the needed graft will be marked by a #15c blade and then diode laser de-epithelization will take place. The de-epithelized area will be then harvested using a # 15c blade. The donor site will be covered by cyanoacrylate tissue adhesive dressing .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunnelingwith subepithelial connective tissue graf
Description: After administration of local anesthesia. A single incision will be made to the bone in a horizontal direction 3mm apical to the gingival margin of the maxillary teeth. The length of the incision will be determined by the dimensions of the graft required. A partial-thickness dissection will be then made within the single incision aiming to harvest an average thickness of two mm subepithelial connective tissue. Then, the graft will be carefully elevated from the palate with the use of the blade. Primary closure will be obtained using 4-0 polyglycolic acid
Study: NCT03712345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1 low dose
Description: Single IV infusions of IFX-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1 high dose
Description: Single IV infusions of IFX-1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02979301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 5 mg or 10 mg tamoxifen per day for 30 days.
Study: NCT02107339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone 0.2 mg/kg administered at induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone 2 mg administered at the conclusion of anesthesia
Study: NCT02200523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SARA electrode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gold cup
Study: NCT02464293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy
Description: An 8 week course of mindfulness-based cognitive therapy
Study: NCT01180088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIGHT HEPATECTOMY WITH CLASSIC APPROACH
Description: The right portal branch and the right branch of the hepatic artery were identified, dissected and divided. Extraparenchymal ligation of pedicles for Sg4 was performed in case of extended right hepatectomy. The falciform and the right triangular ligaments were sectioned and the right liver up to the retrohepatic vena cava was totally mobilized by section and sutures of the accessory right hepatic veins. The right hepatic vein was controlled in an extrahepatic plane and encircled with a tape. At the end of parenchymal transection right hepatic vein was sectioned with endovascular stapler. The right bile duct and middle hepatic vein (in case of extended right hepatectomy) were divided intraparenchymally
Study: NCT02363192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention and pharmacist support
Description: Patients randomised to this group will undergo an asthma assessment to assess asthma control, adherence and inhaler technique, by an Advanced Clinical Pharmacist specialising in Respiratory Medicine.
Study: NCT03231722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: 6 mg/kg iv over 60 minutes, day 1
Study: NCT01150292

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: First period DHA
Description: 400 mg DHA supplementation by day for 2 weeks during the first study period

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Second period DHA
Description: 400 mg DHA supplementation by day for 2 weeks during the second study period
Study: NCT01224028

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01638507

Intervention type: DEVICE
Group type: OTHER
Intervention: Resolute Integrity Stent
Description: Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
Study: NCT02457026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
Study: NCT03477097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition, exercise and social network intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition, exercise and social network intervention
Study: NCT06128473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Contact Lens
Description: Vision Correction
Study: NCT02457026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Triamcinolone Acetonide is a synthetic corticosteroid indicated for treatment of ocular inflammatory conditions, uveitis, sympathetic ophthalmia, and temporal arteritis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Verteporfin is a benzoporphyrin derivative, and is a medication used as a photosensitizer for photodynamic therapy.
Study: NCT01424800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A disposable NIRS (near-infrared spectroscopy) sensor will be applied on the patient's forehead for continuous registration of the cerebral oxygen saturation.
Description: When the patient is on CPB, pressure and/or flow will be changed while continuously measuring ScO2. Temperature, CO2 , arterial oxygen content, hematocrit and anesthesia will be kept constant during the measurements. First, baseline MAP (mean arterial pressure), baseline ScO2 and baseline central venous oxygen saturation (SvO2) are determined. With the interventions, we will induce a change of 20% in MAP and/or flow. This is within the normal range during operations. Changes in blood pressure will be obtained by the use of vasoactive agents (sodiumnitroprusside for blood pressure decrease and phenylephrine for blood pressure increase). Flow is regulated by manual control of the pump flow. Values of the different variables will be obtained after a 5 min stabilisation period. Flow/pressure interventions will be randomized.
Study: NCT04750421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transillumination Venolux®
Description: Transillumination Venolux® method was used on the other half of the face before injections to visualize veins.
Study: NCT03231722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg iv over 60 minutes, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 150 mg/sqm iv over 60 minutes day 1
Study: NCT04180358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Native STAND
Description: Native STAND is a comprehensive sexual health curriculum for Native high school students that focuses on sexually transmitted infections, HIV/AIDS, and teen pregnancy prevention, while also covering drug and alcohol use, suicide, and dating violence. Twenty-seven sessions support healthy decision-making through interactive discussions and activities that promote diversity, self-esteem, goals and values, team building, negotiation and refusal skills, and effective communication. Sessions will be conducted in regular Physical Education and/or Health Education classes during classroom/school hours.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Regular Health/Physical Education Curriculum
Description: General health and physical education curriculum provided by New Mexico's Public Education Department.
Study: NCT03246893

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Noninvasive positive pressure ventilation
Description: Noninvasive positive pressure ventilation will apply via a face mask with initial setting as the following:~Inspiratory pressure 6-8 cmH2O Expiratory pressure 3-5 cmH2O FiO2 30-60% Respiratory rate 12-16 per min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow oxygen nasal cannula
Description: High flow oxygen nasal cannula will apply to patient via a nasal cannula with initial setting as the following:~Temperature 37 degree celsius Flow 30 liter per min FiO2 40-60%
Study: NCT02592356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Study: NCT00659997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Single oral dose of 400mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levamisole
Description: Single oral dose of 2.5mg/kg
Study: NCT00106197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Participants will start with 150 mg daily. If no adverse symptoms, dosage will be increased to twice daily. Treatment will last for 8 weeks.
Study: NCT03231722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/sqm iv over 60 minutes day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/sqm iv over 2 hours day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: l-leucovorin
Description: 200 mg/sqm iv over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-leucovorin
Description: 200 mg/sqm iv over 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 400 mg/sqm iv bolus, day 1 followed by 2400 mg/sqm 48 h-continuous infusion, starting on day 1;
Study: NCT03748355

Intervention type: GENETIC
Group type: OTHER
Intervention: Pharmacogentic Analysis
Description: Participant will complete a buccal swab and it will be sent off to OneOme for analysis. When the results are available, the study investigators will review the medications for potential drug-drug and drug-genotype interactions. The risk for interactions will be classified as low, medium or high. The investigators will then communicate to the clinical team taking care of the patient these results and whether medication changes are recommended to minimize the drug-drug and drug-genotype interactions.
Study: NCT03184259

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Robotic ankle system
Description: Patients will wear the robotic ankle system and undergo 20-minute over-ground walking and 10-minute stair walking.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic ankle system
Description: Patients will wear the robotic ankle system and undergo 20-minute over-ground walking and 10-minute stair walking.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Robotic knee system
Description: Patients will wear the robotic knee system and undergo 20-minute over-ground walking and 10-minute stair walking.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic knee system
Description: Patients will wear the robotic knee system and undergo 20-minute over-ground walking and 10-minute stair walking.
Study: NCT03795831

Intervention type: DEVICE
Intervention: ClearSight feasibility testing
Description: A cuff is placed on a finger of the patient. The ClearSight system uses a volume clamp technology allowing measuring of continuous blood pressure waveform. Note: There will only be observational recordings, no interventions
Study: NCT03968770

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Probiotic (Lactobacillus casei) once daily taken by 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Placebo of Probiotic once daily taken by 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual medical care
Description: NSAIDs, once daily taken and promotion of a healthy lifestyle by 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual medical care
Description: NSAIDs, once daily taken and promotion of a healthy lifestyle by 6 weeks.
Study: NCT04546061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Uplift
Description: Substance use and mental health treatment for young sexual and gender minorities in Durham and Charlotte, NC in conjunction with intensive wraparound services that address factors that influence substance use and mental health among this population.
Study: NCT02606448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Local infiltration of liposomal bupivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block
Description: Pre-operative femoral nerve block
Study: NCT03231722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 400 mg/sqm iv bolus, day 1 followed by 2400 mg/sqm 48 h-continuous infusion, starting on day 1;
Study: NCT04306705

Intervention type: DRUG
Intervention: Tocilizumab
Description: Administered as an intravenous infusion.

Intervention type: OTHER
Intervention: Standard of care
Description: Standard of care therapy per local written policies or guidelines and includes balancing of electrolytes and acid-base, the provision of enteral or parenteral nutrients support, antibiotics therapy, oxygen therapy and noninvasive ventilation.

Intervention type: OTHER
Intervention: Standard of care
Description: Standard of care therapy per local written policies or guidelines and includes balancing of electrolytes and acid-base, the provision of enteral or parenteral nutrients support, antibiotics therapy, oxygen therapy and noninvasive ventilation.

Intervention type: OTHER
Intervention: Standard of care
Description: Standard of care therapy per local written policies or guidelines and includes balancing of electrolytes and acid-base, the provision of enteral or parenteral nutrients support, antibiotics therapy, oxygen therapy and noninvasive ventilation.
Study: NCT03059719

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide injection(Byetta)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PB-119 injection
Study: NCT01844622

Intervention type: OTHER
Group type: OTHER
Intervention: Domperidone
Description: Domperidone dosage may be increased depending on how well the patient responds. However before increasing the dosage, patients will have follow-up EKG to evaluate any possible side effects including irregular heartbeats.